TY - JOUR T1 - Genome-wide polygenic score with <em>APOL1</em> risk genotypes predicts chronic kidney disease across major continental ancestries JF - medRxiv DO - 10.1101/2021.10.25.21265398 SP - 2021.10.25.21265398 AU - Atlas Khan AU - Michael C. Turchin AU - Amit Patki AU - Vinodh Srinivasasainagendra AU - Ning Shang AU - Rajiv Nadukuru AU - Alana C. Jones AU - Edyta Malolepsza AU - Ozan Dikilitas AU - Iftikhar J. Kullo AU - Daniel J. Schaid AU - Elizabeth Karlson AU - Tian Ge AU - James B. Meigs AU - Jordan W. Smoller AU - Christoph Lange AU - David R. Crosslin AU - Gail Jarvik AU - Pavan Bhatraju AU - Jacklyn N. Hellwege AU - Paulette Chandler AU - Laura Rasmussen Torvik AU - Alex Fedotov AU - Cong Liu AU - Christopher Kachulis AU - Noura S. Abul-Husn AU - Judy H. Cho AU - Iuliana Ionita-Laza AU - Ali G. Gharavi AU - Wendy K. Chung AU - George Hripcsak AU - Chunhua Weng AU - Girish Nadkarni AU - Marguerite R. Irvin AU - Hemant K. Tiwari AU - Eimear E. Kenny AU - Nita A. Limdi AU - Krzysztof Kiryluk Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/10/26/2021.10.25.21265398.abstract N2 - Introduction Chronic kidney disease (CKD) is a common complex condition associated with significant morbidity and mortality in the US and worldwide. Early detection is critical for effective prevention of kidney disease progression. Polygenic prediction of CKD could enhance screening and prevention of kidney disease progression, but this approach has not been optimized for risk prediction in ancestrally diverse populations.Methods We developed and validated a genome-wide polygenic score (GPS) for CKD defined by estimated glomerular filtration rate (eGFR) &lt;60 mL/min/1.73m2 using common variant association statistics from GWAS for eGFR combined with information on APOL1 risk genotypes. The score was designed to ensure transferability across major continental ancestries, genotyping platforms, imputation panels, and phenotyping strategies, and was tested following ClinGen guidelines. The polygenic component of the score was developed and optimized using 28,047 cases and 251,772 controls (70% of UK Biobank participants of European ancestry), while the weights for APOL1 effects were derived based on UK Biobank participants of African ancestry (967 cases and 6,191 controls). We tested the performance of the score in 15 independent testing cohorts, including 3 cohorts of European ancestry (total 23,364 cases and 117,883 controls), 6 cohorts of African ancestry (4,268 cases and 10,276 controls), 4 cohorts of Asian ancestry (1,030 cases and 9,896 controls), and 2 Hispanic/Latinx cohorts (1,492 cases and 2,984 controls).Results We demonstrated the risk score transferability with reproducible performance across all independent testing cohorts. In the meta-analyses, disease odds ratios per standard deviation of the score were estimated at 1.49 (95%CI: 1.47-1.50, P&lt;1.0E-300) for European, 1.32 (95%CI: 1.26-1.38, P=1.8E-33) for African, 1.59 (95%CI: 1.52-1.67, P=1.3E-30) for Asian, and 1.42 (95%CI: 1.33-1.51, P=4.1E-14) for Latinx cohorts. The top 2% cutoff of the GPS was associated with nearly 3-fold increased risk of CKD across all major ancestral groups, the degree of risk that is equivalent to a positive family history of kidney disease. In African-ancestry cohorts, APOL1 risk genotype and the polygenic risk components of the GPS had additive effects on the risk of CKD with no significant interactions. We also observed that individuals of African ancestry had a significantly higher polygenic risk score for CKD compared to other populations, even without accounting for APOL1 variants.Conclusions By combining APOL1 risk genotypes with the available GWAS for renal function, we designed, optimized, and validated a GPS predictive of CKD across four major continental ancestries. With the upper tail of the GPS distribution associated with disease risk equivalent to a positive family history, this score could be used for clinically meaningful risk stratification.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by the National Human Genome Research Institute (NHGRI) Electronic Medical Records and Genomics-IV (eMERGE-IV grants 2U01HG008680-05, 1U01HG011167-01, 1U01HG011176-01). Additional sources of funding included UG3DK114926 (KK), RC2DK116690 (KK), R01LM013061 (CW, KK), K25DK128563 (AK) and UL1TR001873 (AK, KK), R01HL151855 (JBM), UM1DK078616 (JBM). The REGARDS (R01HL136666), HyperGEN (R01HL055673), GenHAT (R01HL123782), and WPC (R01HL092173, K24HL133373) studies were all supported by the National Heart, Lung, and Blood Institute (NHLBI). Parts of this study have been conducted using the UKBB Resource under UKBB project ID number 41849. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe final formulation of the GPS for CKD along with the standardized metrics of performance were deposited in the GPS catalogue, accession number pending. ER -